Comparing Two Ways to Give GM-CSF for Breast Cancer Treatment
Author Information
Author(s): AH Honkoop, K Hoekman, J Wagstaff, CJ van Groeningen, JB Vermorken, E Boven, HM Pinedo
Primary Institution: University Hospital Vrije Universiteit Amsterdam
Hypothesis
Is subcutaneous administration of GM-CSF less toxic and equally effective compared to continuous intravenous administration in patients with advanced breast cancer?
Conclusion
Subcutaneous GM-CSF is preferred over continuous intravenous GM-CSF due to lower toxicity.
Supporting Evidence
- Patients receiving continuous intravenous GM-CSF required more erythrocyte and platelet transfusions.
- Subcutaneous GM-CSF resulted in a lower incidence of neutropenic fever.
- Performance status deterioration was significantly worse in patients receiving continuous intravenous GM-CSF.
Takeaway
This study looked at two ways to give a medicine called GM-CSF to help breast cancer patients. It found that giving it under the skin is safer than giving it through an IV.
Methodology
Patients with advanced breast cancer were treated with doxorubicin and cyclophosphamide along with GM-CSF, comparing continuous intravenous and subcutaneous administration.
Potential Biases
Potential bias due to non-randomized design and patient selection.
Limitations
The study was not randomized, which may affect the reliability of the results.
Participant Demographics
Women aged 18 to 65 with locally advanced or metastatic breast cancer.
Statistical Information
P-Value
p=0.04 for platelet counts
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website